{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:26:05Z","timestamp":1785367565969,"version":"3.55.0"},"reference-count":84,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure remains a major cause of morbidity and mortality worldwide despite substantial advances in pharmacological and device-based therapies. Distinct phenotypes, including heart failure with reduced ejection fraction, mildly reduced ejection fraction, and preserved ejection fraction, differ markedly in underlying pathophysiology, clinical presentation, and therapeutic responsiveness. Therefore, a deeper understanding of disease mechanisms is essential for guiding evolving management strategies and identifying novel therapeutic targets. This narrative review synthesizes contemporary evidence on the pathogenesis and management of heart failure, integrating mechanistic biology with phenotype-specific treatment effects and acute\u2013chronic disease transitions to provide a translational framework for care. Key clinical trials, guideline documents, and mechanistic studies were identified through structured searches of major medical databases and review of international guideline updates, with emphasis on recent advances in disease-modifying therapies, inflammatory mechanisms, and emerging treatment strategies across heart failure phenotypes. Heart failure with reduced ejection fraction is characterized predominantly by myocyte loss, adverse ventricular remodeling, and neurohormonal activation, with robust evidence supporting combined disease-modifying pharmacotherapy and selected device-based interventions. In contrast, heart failure with preserved ejection fraction is driven largely by systemic comorbidities, endothelial dysfunction, and myocardial fibrosis, contributing to impaired ventricular compliance and limited evidence-based treatment options. Sodium\u2013glucose cotransporter 2 inhibitors have demonstrated consistent reductions in symptoms and hospitalizations across the spectrum of ejection fractions, representing a major advance in management. However, translation of mechanistic insights into effective therapies has been variable. Broad anti-inflammatory strategies targeting cytokine pathways have yielded mixed or neutral outcomes. In contrast, more targeted approaches, including interleukin-1 inhibition, inflammasome modulation, and mitochondrial-directed therapies, show emerging but heterogeneous signals that warrant phenotype-specific evaluation. Heart failure is a heterogeneous syndrome that requires biologically informed, phenotype-specific approaches. Thus, by linking dominant mechanisms to therapeutic response and highlighting the limitations of current evidence, this review aims to advance understanding beyond descriptive summaries and to outline priorities for future precision-oriented heart failure care.<\/jats:p>","DOI":"10.31083\/rcm49678","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:06:15Z","timestamp":1783422375000},"source":"Crossref","is-referenced-by-count":1,"title":["Exploration of the Pathogenesis and Treatment of Heart Failure"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1891-9879","authenticated-orcid":true,"given":"Jordan M","family":"Tumes","sequence":"first","affiliation":[{"name":"University of Liverpool, L69 7ZX Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit","family":"Ravishankar","sequence":"additional","affiliation":[{"name":"University of Liverpool, L69 7ZX Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael H","family":"Khan","sequence":"additional","affiliation":[{"name":"University of Liverpool, L69 7ZX Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-0198","authenticated-orcid":true,"given":"Ahmed R","family":"Gonnah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-7523","authenticated-orcid":true,"given":"David H","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Liverpool, L69 7ZX Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2023; 118: 3272\u20133287.","DOI":"10.1093\/cvr\/cvac013"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Metra M, Teerlink JR. Heart failure. Lancet (London, England). 2017; 390: 1981\u20131995.","DOI":"10.1016\/S0140-6736(17)31071-1"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Bellanca L, Linden S, Farmer R. Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data - the PULSE study. BMC Cardiovascular Disorders. 2023; 23: 374.","DOI":"10.1186\/s12872-023-03337-1"},{"key":"ref4","unstructured":"British Heart Foundation. Heart & Circulatory Disease Statistics (compendium, 2023\/2024 editions). Excellent UK tables and time-series. 2024. Available at: https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-statistics-compendium-2023.pdf (Accessed: 10 November 2025). https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-statistics-compendium-2023.pdf"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. Global epidemiology of heart failure. Nature Reviews. Cardiology. 2024; 21: 717\u2013734.","DOI":"10.1038\/s41569-024-01046-6"},{"key":"ref6","unstructured":"National Institute for Health and Care Excellence (NICE). Acute heart failure: diagnosis and management (NICE Clinical Guidelines, No. 187). 2021. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK575857\/ (Accessed: 24 December 2025). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK575857\/"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Fletcher RA, Rockenschaub P, Neuen BL, Walter IJ, Conrad N, Mizani MA, et al. Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records. The Lancet. Public Health. 2024; 9: e871\u2013e885.","DOI":"10.1016\/S2468-2667(24)00215-9"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. European Journal of Heart Failure. 2021; 23: 352\u2013380.","DOI":"10.1002\/ejhf.2115"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Narayan SI, Terre GV, Amin R, Shanghavi KV, Chandrashekar G, Ghouse F, et al. The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review. Cureus. 2023; 15: e45719.","DOI":"10.7759\/cureus.45719"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. Journal of the American College of Cardiology. 2023; 81: 1810\u20131834.","DOI":"10.1016\/j.jacc.2023.01.049"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014; 129: 2380\u20132387.","DOI":"10.1161\/CIRCULATIONAHA.113.006855"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine. 2022; 387: 1089\u20131098.","DOI":"10.1056\/NEJMoa2206286"},{"key":"ref13","unstructured":"McDonagh T, Hardman S. National Heart Failure Audit (NHFA) 2022 summary report. 2022. Available at: https:\/\/www.hqip.org.uk\/wp-content\/uploads\/2022\/06\/NHFA-DOC-2022-FINAL.pdf (Accessed: 7 November 2025). https:\/\/www.hqip.org.uk\/wp-content\/uploads\/2022\/06\/NHFA-DOC-2022-FINAL.pdf"},{"key":"ref14","unstructured":"British Heart Foundation. Hospital admissions rise by a third in five years. 2019. Available at: https:\/\/www.bhf.org.uk\/what-we-do\/news-from-the-bhf\/news-archive\/2019\/november\/heart-failure-hospital-admissions-rise-by-a-third-in-five-years (Accessed: 21 December 2025). https:\/\/www.bhf.org.uk\/what-we-do\/news-from-the-bhf\/news-archive\/2019\/november\/heart-failure-hospital-admissions-rise-by-a-third-in-five-years"},{"key":"ref15","unstructured":"Chahine J, Alvey H. Left Ventricular Failure. 2025. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537098\/ (Accessed: 4 December 2025). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537098\/"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Foschi M, Di Mauro M, Tancredi F, Capparuccia C, Petroni R, Leonzio L, et al. The Dark Side of the Moon: The Right Ventricle. Journal of Cardiovascular Development and Disease. 2017; 4: 18.","DOI":"10.3390\/jcdd4040018"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Pitoulis FG, Terracciano CM. Heart Plasticity in Response to Pressure- and Volume-Overload: A Review of Findings in Compensated and Decompensated Phenotypes. Frontiers in Physiology. 2020; 11: 92.","DOI":"10.3389\/fphys.2020.00092"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Papapostolou S, Kearns J, Costello BT, O'Brien J, Gutman SJ, Nanayakarra S, et al. Comparison of Pressure vs Volume Overload Ventricular Wall Stress in Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2024; 84: 635\u2013644.","DOI":"10.1016\/j.jacc.2024.04.068"},{"key":"ref19","unstructured":"American Heart Association. Classes and Stages of Heart Failure. 2025. Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/classes-of-heart-failure (Accessed: 14 November 2025). https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/classes-of-heart-failure"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111: 2837\u20132849.","DOI":"10.1161\/CIRCULATIONAHA.104.500546"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nature Reviews. Cardiology. 2017; 14: 30\u201338.","DOI":"10.1038\/nrcardio.2016.163"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. American Journal of Physiology. Cell Physiology. 2007; 292: C82\u2013C97.","DOI":"10.1152\/ajpcell.00287.2006"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. Journal of the American College of Cardiology. 2005; 46: 1785\u20131791.","DOI":"10.1016\/j.jacc.2005.02.095"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Vasquez N, Carter S, Grodin JL. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis. Current Heart Failure Reports. 2020; 17: 67\u201376.","DOI":"10.1007\/s11897-020-00458-y"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Henry A, Mo X, Finan C, Chaffin MD, Speed D, Issa H, et al. Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes. Nature Genetics. 2025; 57: 815\u2013828.","DOI":"10.1038\/s41588-024-02064-3"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Mukhopadhyay S, Dixit P, Khanom N, Sanghera G, McGurk KA. The Genetic Factors Influencing Cardiomyopathies and Heart Failure across the Allele Frequency Spectrum. Journal of Cardiovascular Translational Research. 2024; 17: 1119\u20131139.","DOI":"10.1007\/s12265-024-10520-y"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Tayal U, Newsome S, Buchan R, Whiffin N, Halliday B, Lota A, et al. Phenotype and Clinical Outcomes of Titin Cardiomyopathy. Journal of the American College of Cardiology. 2017; 70: 2264\u20132274.","DOI":"10.1016\/j.jacc.2017.08.063"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023; 44: 3503\u20133626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a\/c mutation carriers a European cohort study. Journal of the American College of Cardiology. 2012; 59: 493\u2013500.","DOI":"10.1016\/j.jacc.2011.08.078"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Bers DM. Cardiac excitation-contraction coupling. Nature. 2002; 415: 198\u2013205.","DOI":"10.1038\/415198a"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Lam CSP, Docherty KF, Ho JE, McMurray JJV, Myhre PL, Omland T. Recent successes in heart failure treatment. Nature Medicine. 2023; 29: 2424\u20132437.","DOI":"10.1038\/s41591-023-02567-2"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Hiraiwa H, Okumura T, Murohara T. Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review. American Journal of Cardiovascular Drugs : Drugs, Devices, and other Interventions. 2024; 24: 343\u2013369.","DOI":"10.1007\/s40256-024-00641-9"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Braunwald E. The war against heart failure: the Lancet lecture. Lancet (London, England). 2015; 385: 812\u2013824.","DOI":"10.1016\/S0140-6736(14)61889-4"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"House AA, Wanner C, Sarnak MJ, Pi\u00f1a IL, McIntyre CW, Komenda P, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2019; 95: 1304\u20131317.","DOI":"10.1016\/j.kint.2019.02.022"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Anderson M, Forrest Parrott C, Haykowsky MJ, Brubaker PH, Ye F, Upadhya B. Skeletal muscle abnormalities in heart failure with preserved ejection fraction. Heart Failure Reviews. 2023; 28: 157\u2013168.","DOI":"10.1007\/s10741-022-10219-9"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Cui X, Hu Y, Xu Y, Yang L, Chatterjee E, Li G, et al. Systemic Interactions in HFpEF: A Multiorgan Perspective on Pathways and Therapeutic Targets. Journal of Cardiovascular Translational Research. 2025; 18: 1876\u20131892.","DOI":"10.1007\/s12265-025-10699-8"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Khan MS, Javaid SS, Dinani A, Wegermann K, Pandey A, Bhatt AS, et al. The Basics of Metabolic Dysfunction-Associated Steatotic Liver Disease for Cardiologists: Pathophysiology, Diagnosis, and Treatment. Journal of the American College of Cardiology. 2025; 86: 1861\u20131884.","DOI":"10.1016\/j.jacc.2025.08.100"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2023; 72: 372\u2013380.","DOI":"10.1136\/gutjnl-2022-327672"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2018; 20: 16\u201337.","DOI":"10.1002\/ejhf.1029"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Vachi\u00e9ry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. The European Respiratory Journal. 2019; 53: 1801897.","DOI":"10.1183\/13993003.01897-2018"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Li Y, Lin Z, Li Y. Visceral obesity and HFpEF: targets and therapeutic opportunities. Trends in Pharmacological Sciences. 2025; 46: 337\u2013356.","DOI":"10.1016\/j.tips.2025.02.005"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Zheng W, Qi Q, Li J, He C, Fan H. Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies. Diabetology & Metabolic Syndrome. 2025; 17: 336.","DOI":"10.1186\/s13098-025-01917-z"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Wu Y, Song M, Chen X, Chen W, Wu M, Lin L. Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review. Current Heart Failure Reports. 2025; 22: 33.","DOI":"10.1007\/s11897-025-00722-z"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Theodorakis N, Kreouzi M, Hitas C, Anagnostou D, Nikolaou M. Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review. Diagnostics (Basel, Switzerland). 2024; 14: 2677.","DOI":"10.3390\/diagnostics14232677"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Rafaqat S. Adipokines and Their Role in Heart Failure: A Literature Review. The Journal of Innovations in Cardiac Rhythm Management. 2023; 14: 5657\u20135669.","DOI":"10.19102\/icrm.2023.14111"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Packer M. The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. Journal of the American College of Cardiology. 2025; 86: 1269\u20131373.","DOI":"10.1016\/j.jacc.2025.06.055"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Reddy YNV, Frantz RP, Hemnes AR, Hassoun PM, Horn E, Leopold JA, et al. Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2025; 85: 1774\u20131788.","DOI":"10.1016\/j.jacc.2025.03.530"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Nagatomo Y, Tang WHW. Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis. Journal of Cardiac Failure. 2015; 21: 973\u2013980.","DOI":"10.1016\/j.cardfail.2015.09.017"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. Journal of the American College of Cardiology. 2007; 50: 1561\u20131569.","DOI":"10.1016\/j.jacc.2007.07.016"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic Gut Flora in Patients With Chronic Heart Failure. JACC. Heart Failure. 2016; 4: 220\u2013227.","DOI":"10.1016\/j.jchf.2015.10.009"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nature Reviews. Cardiology. 2019; 16: 137\u2013154.","DOI":"10.1038\/s41569-018-0108-7"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Tr\u00f8seid M, Andersen G\u00d8, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. EBioMedicine. 2020; 52: 102649.","DOI":"10.1016\/j.ebiom.2020.102649"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Larson KF, Malik A, Brozovich FV. Aging and Heart Failure with Preserved Ejection Fraction. Comprehensive Physiology. 2022; 12: 3813\u20133822.","DOI":"10.1002\/cphy.c210035"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circulation Research. 2018; 122: 624\u2013638.","DOI":"10.1161\/CIRCRESAHA.117.311586"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Packer M, Schiattarella GG, Borlaug BA. What Exactly Is Cardiometabolic HFpEF: A Phenotype or an Endotype? Circulation. Heart Failure. 2026; 19: e014031.","DOI":"10.1161\/CIRCHEARTFAILURE.125.014031"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019; 381: 1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. Journal of the American College of Cardiology. 2021; 77: 1381\u20131392.","DOI":"10.1016\/j.jacc.2021.01.033"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Cohen LP, Isaza N, Hernandez I, Lewis GD, Ho JE, Fonarow GC, et al. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiology. 2023; 8: 419\u2013428.","DOI":"10.1001\/jamacardio.2023.0077"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021; 385: 1451\u20131461.","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref61","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management (NICE Clinical Guidelines, No. 106). 2025. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK618692\/ (Accessed: 22 December 2025). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK618692\/"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Kido K, Hashiguchi M, Guglin M. Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials. JACC. Advances. 2025; 4: 102356.","DOI":"10.1016\/j.jacadv.2025.102356"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023; 44: 3627\u20133639.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Tang AB, Lewsey SC, Yancy CW, Heidenreich PA, Greene SJ, Allen LA, et al. Get With The Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead. Circulation. Heart Failure. 2025; 18: e012936.","DOI":"10.1161\/CIRCHEARTFAILURE.125.012936"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet (London, England). 2021; 398: 991\u20131001.","DOI":"10.1016\/S0140-6736(21)01754-2"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Bavendiek U, Thomas NH, Berliner D, Liu X, Schwab J, Rieth A, et al. DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials. European Journal of Heart Failure. 2025; 27: 1224\u20131233.","DOI":"10.1002\/ejhf.3679"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, et al. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation. 2025; 152: 1411\u20131422.","DOI":"10.1161\/CIRCULATIONAHA.125.076575"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England Journal of Medicine. 2023; 389: 1069\u20131084.","DOI":"10.1056\/NEJMoa2306963"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstr\u00f8m SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet (London, England). 2024; 403: 1635\u20131648.","DOI":"10.1016\/S0140-6736(24)00469-0"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. The New England Journal of Medicine. 2024; 390: 1394\u20131407.","DOI":"10.1056\/NEJMoa2313917"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Waqas SA, Sohail MU, Saad M, Minhas AMK, Greene SJ, Fudim M, et al. Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of Cardiac Failure. 2025; 31: 1076\u20131080.","DOI":"10.1016\/j.cardfail.2025.01.022"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Behers BJ, Sanchez C, Hozayen O, Hozayen Y, Kammer R, Corrigan WT, et al. Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease. 2026; 13: 103.","DOI":"10.3390\/jcdd13020103"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Cikes M, Brugts JJ, Claggett B, Jorde UP, Milicic D, Planinc I, et al. Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy: Primary Results of the ENVAD-HF Trial. JACC. Heart Failure. 2025; 13: 102657.","DOI":"10.1016\/j.jchf.2025.102657"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Pe\u00f1a-Pe\u00f1a ML, et al. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. The New England Journal of Medicine. 2025; 393: 949\u2013960.","DOI":"10.1056\/NEJMoa2504654"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2025; 406: 1341\u20131350.","DOI":"10.1016\/S0140-6736(25)01665-4"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet (London, England). 2025; 406: 1351\u20131362.","DOI":"10.1016\/S0140-6736(25)01682-4"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109: 1594\u20131602.","DOI":"10.1161\/01.CIR.0000124490.27666.B2"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine. 2017; 377: 1119\u20131131.","DOI":"10.1056\/NEJMoa1707914"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, et al. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circulation. Heart Failure. 2017; 10: e004373.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Wohlford GF, Van Tassell BW, Billingsley HE, Kadariya D, Canada JM, Carbone S, et al. Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. Journal of Cardiovascular Pharmacology. 2020; 77: 49\u201360.","DOI":"10.1097\/FJC.0000000000000931"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences. 2025; 26: 944.","DOI":"10.3390\/ijms26030944"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. The New England Journal of Medicine. 2019; 381: 2497\u20132505.","DOI":"10.1056\/NEJMoa1912388"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet (London, England). 2016; 387: 1178\u20131186.","DOI":"10.1016\/S0140-6736(16)00082-9"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Henry TD, Chung ES, Alvisi M, Sethna F, Murray DR, Traverse JH, et al. Cardiotropic AAV gene therapy for heart failure: a phase 1 trial. Nature Medicine. 2025; 31: 3845\u20133852.","DOI":"10.1038\/s41591-025-04011-z"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM49678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:07:21Z","timestamp":1783422441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM49678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02354-9"],"URL":"https:\/\/doi.org\/10.31083\/rcm49678","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"49678"}}